tirzepatide
tirzepatide is listed in the FDA National Drug Code directory with 141 NDC codes, marketed under brand names including Zepbound, Mounjaro, Mounjaro KwikPen. Available dosage forms: injection, solution, powder.
Drug details
- Generic Name
- tirzepatide
- Brand Names
- Zepbound, Mounjaro, Mounjaro KwikPen, ZEPBOUND, Zepbound KwikPen, MOUNJARO
- Application Number
- NDA217806
- Sponsor
- Eli Lilly And Company
- NDC Codes
- 141
- Dosage Forms
- INJECTION, SOLUTION, POWDER
- Routes
- SUBCUTANEOUS
- Active Ingredients
- TIRZEPATIDE
Indications and Usage
1 INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ( 1 ) Limitations of Use: Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.